Acetyl Gastric Inhibitory Peptide (human) (TFA) is a synthetic, chemically modified human gastric inhibitory peptide [1]. Acetyl Gastric Inhibitory Peptide (human) (TFA) is a physiological incretin hormone that can effectively stimulate insulin release in a glucose-dependent manner [2]. Acetyl Gastric Inhibitory Peptide (human) (TFA) is commonly used in metabolic disease research and diabetes drug development [3-4].
In adult male wistar rats, Acetyl Gastric Inhibitory Peptide (human) (TFA) (25nM/kg; ip; single injection) significantly reduces plasma glucose concentration [5].
References:
[1]. Flatt PR, O'harte FP, Utech Ltd. Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function. United States patent application US 11/991,638. 2009 Nov 19.
[2]. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 2009 Sep; 52: 1724-1731.
[3]. Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020 Mar; 125: 170202.
[4]. O'Harte F, Gault V, Parker J, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep; 45: 1281-1291.
[5]. Cassidy RS, Irwin N, Flatt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Biological chemistry. 2008 Feb; 389(2): 189-193.
Acetyl Gastric Inhibitory Peptide (human) (TFA)是一种合成的、化学修饰的人类抑胃肽 [1]。Acetyl Gastric Inhibitory Peptide (human) (TFA)是一种生理性肠促胰岛素激素，能够以葡萄糖依赖性方式有效刺激胰岛素释放 [2]。Acetyl Gastric Inhibitory Peptide (human) (TFA)常用于代谢疾病研究和糖尿病药物研发 [3-4]。
在成年雄性Wistar大鼠中，Acetyl Gastric Inhibitory Peptide (human) (TFA)（25nM/kg；腹腔注射；单次注射）显著降低血浆葡萄糖浓度 [5]。